SceneRay Medical won the Ernst & Young Fudan Most Promising Enterprise Award, demonstrating strong innovation capabilities

On September 26, 2023, a grand event focusing on new energy, new technologies, and new developments was held in Shanghai. The Ernst & Young Fudan Most Promising Companies 2023 Awards Ceremony and High-Growth Companies Themed Seminar unveiled their highly anticipated awards. A group of leading companies in innovative fields, recognized for their outstanding performance and strength, were honored with this highly anticipated award.

This year's selection included 18 winners of the "Most Promising Company Award" and 14 winners of the "Most Promising Seed Company Award."

At the awards ceremony, Professor Li Ruoshan of the Fudan University School of Management stated, "There are no bad industries, only bad companies. We must be companies of the times."

SceneRay Medical is one such company—an innovative enterprise integrating the R&D, production, and sales of deep brain stimulation systems. Not only does it possess its own independently developed neurostimulator, it also innovatively introduces "dual-target combined stimulation" technology, which has been granted Breakthrough Device designation for neuromodulation by the US FDA. Jingyu Medical is also expanding into the field of mental illness. Jingyu Medical was awarded the EY Fudan Most Promising Enterprise Award for its outstanding innovation and promising market prospects.

Receiving this award is a significant milestone in SceneRay Medical's development, serving as both a recognition of SceneRay past efforts and an encouragement for future development. Going forward, Jingyu Medical will continue to uphold its innovative philosophy, enhance its technological innovation capabilities, deepen its research in brain science, actively expand into the brain disease market, and contribute more Chinese strength to the development of global medical technology.